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It should be apparent that determining the reproductive risks of an exposure during pregnancy or the
cause of a child’s congenital malformations is not a simple process. It involves a careful analysis of the
medical and scientiﬁc literature pertaining to the reproductive toxic effects of exogenous agents in
humans and animals, as well as an evaluation of the exposure and the biological plausibility of the
concern of an increased risk or a causal connection between the exposure and a child’s congenital
malformations. It also involves having available a detailed physical examination of the malformed infant
or child and a review of the scientiﬁc literature pertaining to genetic and environmental causes of the
malformations in question. Abridged counseling on the basis of superﬁcial and incomplete analyses is a
disservice to the family. Experienced counselors understand that their primary task is to educate the
pregnant women or family members concerning the risk of an environmental exposure. The counselor
should advise them on the options available, but not on which option to select.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
In 1944, during World War II, I received my draft notice for in-
duction into the armed forces, which would occur in mid 1945. At
the age of 15 years, I applied to the University of Rochester, since I
had passed all the high school senior courses which included
advanced physics, biology and chemistry. In June 1944, I was a
freshman at the University and obtained a part-time position at the
Manhattan Project Research facility in Rochester in the genetics and
embryology divisions. Whereas all the employees at the University
of Rochester were investigating the biological effects of ionizing
radiation and the entire research staff had the highest level of se-
curity clearance, none of the staff were aware that researchers in
Los Alamos were attempting to develop an atomic bomb. After the
war ended in 1945, the Manhattan Project became one of the
Atomic Energy Commission (AEC) facilities at the University. In
1949, I entered medical school but continued my embryology ra-
diation research. The head of the division, Dr James Wilson, offered
me the opportunity to be his graduate student in the summer of
1950 and Wilson spent the summer intensively training me in allAll rights reserved.the experimental techniques used in that division. At the end of the
summer, Dr Wilson announced that he had accepted a position at
the University of Cincinnati. Rather than close the division, the
Administration appointed me the Head of the Division. I had a
budget, a technician and secretarial support and I taught the Uni-
versity of Rochester medical students embryology during the next
four years while I was in Rochester completing my medical and
graduate degrees. During these four years my national and inter-
national counseling effort began at the University of Rochester.
The only other major AEC facility in the country interested in
radiation effects on reproduction was at Liane Russell’s excellent
laboratory in Oak Ridge, Tennessee. However, she was extensively
involved in pursuing her research. So the calls and letters all came
to Rochester, and then to the Massachusetts General Hospital
where I was a resident physician and the Walter Reed Army Insti-
tute of Research where I was the head of the Radiation Biology
Section for my two years of Army service from 1955 until 1957. I
arrived at The Jefferson Medical College in 1957 and have been
there for 56 years. In the 1950s there were practically no educa-
tional programs in medical school or graduate school that per-
tained to the evaluation of the risks of reproductive and
developmental toxicants or counseling families with regard to the
presence or absence of risks from these exposures. The concept of
professional counseling was still in its infancy.
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USA: When did counseling with regard to reproductive and
developmental toxicant exposure become a recognized and
necessary skill?
Medical education in the USA received a major impetus
following the publication of Abraham Flexner’s (1910) monograph
that was commissioned by the Carnegie Foundation for the
Advancement of Teaching [1]. Prior to being contacted by the Car-
negie Foundation, Flexner graduated from Johns Hopkins in 1885 at
the age of 19 and crystallized in his mind the components of quality
higher educational programs: small classes, personal attention and
hands-on teaching. He returned to Louisville and founded a med-
ical school using these principles. The graduates proved to be em-
issaries of what quality education can accomplish. It was these early
successes that convinced the Carnegie Foundation that Flexner was
the scholar who could improve medical education. Following the
implementation of the Flexner Report many rural medical schools
closed. Many physicians are unaware that Flexner was not a
physician nor did he have an advanced degree. However, he was a
brilliant teacher and scholar.
Over the next 50 years the Flexner model of medical education
evolved into the bioscience model of medical education and med-
ical practice. High quality basic science education and research
‘could provide all the answers’, so that physicians could diagnose,
ameliorate, treat or cure medical problems with which they
encountered.
Unfortunately, the bioscience model is incomplete and can
result in a signiﬁcant portion of the patient population being
dissatisﬁed with their care. This was evident to George Engle at the
University of Rochester. He was trained in psychiatry and internal
medicines and published many articles about the biopsychosocial
model of health care delivery that reﬂected his interest in psy-
chosomatic medicine [2]. At the University of Rochester Engle
established the ‘medical psychiatric liaison service’ staffed by in-
ternists and psychiatrists. Engle indicated that he would prefer
having physicians with behavioral training rounding on the other
clinical services rather than on the psychiatry service. Engle was
adamant that you cannot ignore the impact of the environment on
the patient’s disease or the behavioral defenses available to the
patient. It was clear that Engle believed that compassion and
empathy were important components of the biopsychosocial
model of medical care.
Carl Rogers [3e5] is probably the most important contributor to
the elements of proper counseling since he emphasized the hu-
manistic approach to psychological counseling. If the patients or
contacts do not sense that the counselor is compassionate or
empathetic, their interaction will be less than satisfactory. Exhib-
iting genuine compassion and empathy results in a client-centered
interaction with much greater success in properly communicating
and educating the contact. The client, patient or contact has to
believe that the counselor believes that the contact deserves
respect, which is demonstrated by exhibiting compassion and re-
gard for the contact (unconditional, positive regard) [4]. The
fundamental precepts of Rogerian counseling include congruence
(being genuine in one’s concern), empathy, and unconditional
positive regard [4]. A widely accepted component of genuine
concern in medical counseling is the responsibility of the counselor
to provide core knowledge of the evidence addressing the issue in
question. To be genuinely concerned is to seek and provide reliable
information. A further adaptation of these principles involves
providing an unbiased discussion of the facts surrounding the
problem being addressed. Empathy requires some knowledge of,
and sensitivity to, the social and cultural position of the persons
being counseled.During the ﬁrst 50 years of the twentieth century, the rules of
professional counseling were rarely articulated or taught. It was
only after the writings of Engle and Rogers that the essential fea-
tures of professional counseling were legitimized, whether it per-
tained to psychotherapy, medical care and especially for counseling
contacts concerning reproductive and developmental risks from
environmental exposures.
3. The history of providing counseling to pregnant women
exposed to reproductive and developmental toxicants
(teratogenesis, congenital malformations), and men and
women with preconception exposures (mutagenesis in the
gametes and in the offspring in the next generation)
Individual counseling is part of the practice of clinical medi-
cine. However, at the beginning of the twentieth century there
were very few individuals prepared to counsel patients with re-
gard to the risk of reproductive, developmental and mutagenic
toxicants.
Our laboratory has provided consultations dealing with the risk
of various environmental toxicant exposures during or before
pregnancy since 1950. In 1960 a group 60 scientists interested in
birth defects met at the Slone Kettering Institute in New York City
to discuss their common interests in the causes of birth defects
and decided to create a Birth Defects Society. In 1961 many of
those scientists met in Cincinnati where the charter of the Tera-
tology Society was drafted. Within the Teratology Society a pro-
portion of the membership was interested in providing counseling
to the patient population. There were diverse opinions as to
whether individuals who provided counseling should receive
training and pass a certiﬁcation examination. That issue was never
resolved. However, the problem was partially solved in the 1990s
when the Organization of Teratology Services was formed, which
frequently meets with the Teratology Society at the latter’s annual
meeting. In 2005, the name of OTIS was changed to the Organi-
zation of Teratology Information Specialists. In Europe the Euro-
pean Teratology Society (founded in the 1970s) and European
Network of Teratology Information Services (ENTIS) deﬁne the
counseling organizations in Europe having active scientiﬁc and
counseling programs, as also happens in Japan and Australia. But
none of these organizations professionally certiﬁes individuals to
provide counseling, although some members may be certiﬁed
genetic counselors.
In North America there are many OTIS members and branches.
The Mother Risk program (Motherrisk.org) headed by Dr Gideon
Koren is located at the Hospital for Sick Children and the University
of Toronto. In San Diego, Dr Kenneth Lyon Jones heads the largest
program in California; and in Seattle, the TERIS program was
initiated with a federal grant obtained by Dr Jan Friedman.With the
advent of the Internet, consulting has become more rapid and
efﬁcient. In 2012 the Ask the Expert (ATE) website of the HPS
(Health Physics Society) received about 2 400 000 hits. More than
700 000 prepared answers to questions were downloaded. More
than 1800 contacts were still quite anxious after reading the
website answers and requested a personal consultation. During
2012 our laboratory received its 25 000th consultation. We also
receive consultations by letter, telephone and e-mail unrelated to
the HPS website. From this extensive experience we have learned
that many physicians and other health care counselors are not
prepared to counsel patients concerning reproductive and devel-
opmental risks. Approximately 6e10% of the contacts concerned
about various environmental toxicants had been provided inaccu-
rate information that stimulated unwarranted anxiety that could
have resulted in an unnecessary interruption of a wanted
pregnancy.
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The counselor must be cognizant of many patients’ belief that
congenital malformations are caused by a drug or medication taken
during pregnancy. Counseling patients about reproductive risks
requires a signiﬁcant degree of both knowledge and skill. Physi-
cians must also realize that erroneous counseling by inexperienced
health professionals may be a stimulus to non-meritorious litiga-
tion [6e8].
Unfortunately, some individuals have assumed that if a drug or
chemical causes birth defects in an animal model or in an in-vitro
system at a high dose, then it has the potential for producing
birth defects at any dose. This may be reinforced by the fact that
many teratology studies reported in the literature using several
doses have not determined the no-effect dose.
Ignoring the basic tenets of teratology (Box 1) appears to occur
most frequently in the evaluation of environmental toxic exposures
where the exposure was very low or unknown and the agent has
been reported to be teratogenic at a very high dose or a maternally
toxic dose in animal modes. In most but not all instances, the actual
population exposure is revealed to be orders of magnitude below
the threshold dose observed in animal studies. This has occurred
with 2,4,5,-trichlorophenoxyacetic acid (2,4,5-T, also known as
Agent Orange), polychlorinated biphenyls (PCBs), lead, cadmium,
pesticides, herbicides, veterinary hormones and some industrial
exposures.
Unfortunately, environmental disasters have been responsible
for birth defects or pregnancy loss in exposed populations (methyl
mercury in Japan, PCBs in the Orient, organic mercury in theMiddleBox 1
Principles of teratology.
When evaluating studies dealing with the reproductive and
developmental effects of any environmental agent, impor-
tant principles should guide the analysis of reproductive
human and animal studies. Paramount to this evaluation is
the application of the basic science principles of teratology
and developmental biology:a
1. Exposure to teratogens follows a toxicological doseere-
sponse curve. There is a threshold below which no effect
will be observed, and, as the dose of the teratogen is
increased, both the severity and frequency of reproduc-
tive effects will increase (deterministic effect; tissue
reaction).
2. The period of exposure is critical in determining what
effects will be produced and whether any effects can be
produced by a known teratogen. Some teratogenic ef-
fects have a broad period of sensitivity, others a very
narrow one.
3. Even the most potent teratogenic agent cannot produce
every malformation.
4. Most teratogens have a confined group of congenital
malformations that occur after exposure during a critical
period of embryonic development. This confined group
of malformations is referred to as the syndrome that
describes the agent’s teratogenic effect.
5. Whereas a group of malformations may suggest the
possibility of certain teratogens, they cannot definitively
confirm the causal agent. On the other hand, the pres-
ence of certain malformations can eliminate the possi-
bility that a particular teratogenic agent was responsible.
aSource: Brent [52].East, lead poisoning in the nineteenth and early twentieth cen-
turies) and there are examples of teratogenic drugs and chemicals
having been introduced (Table 1) [10e17]. Therefore, we can never
generalize as to whether a chemical or drug is safe or hazardous
unless we know the magnitude and stage of the exposure.
Before their baby is born, parents may be concerned about the
risks of various environmental exposures. If the child is born with
congenital malformations they may question whether there was a
causal relationship with an environmental exposure.
4.1. Scholarly evaluation
When a counselor responds to a parent’s inquiry (‘What caused
my child’s birth defect?’), the physician should respond in the same
scholarlymanner that would be utilized in performing a differential
diagnosis for any clinical problem. Physicians have a protocol for
evaluating complex clinical problems; i.e. ‘fever of unknown origin’,
‘failure to thrive’, ‘congestive heart failure’, or ‘respiratory distress’
(Box 2).
If a mother of a malformed infant had some type of exposure
during pregnancy, such as a diagnostic radiological examination or
medication utilized during pregnancy, the consulting physician
should not support or suggest the possibility of a causal relation-
ship before performing a complete evaluation (Box 3). Likewise, if a
pregnant woman who had not yet delivered had some type of
exposure during pregnancy, the consulting physician should not
support or suggest the possibility that the fetus is at increased risk
before performing a complete evaluation.
As mentioned previously, only a small percentage of birth de-
fects is due to prescribed drugs, chemicals and physical agents
(Tables 2 and 3). Even when the drug is listed as a teratogen, it has
to have been administered during the sensitive period of devel-
opment for that drug and above the threshold dose for producing
teratogenesis. Furthermore, the malformations in the child should
be the malformations that are included in the teratogenic syn-
drome produced by that drug. It should be emphasized that a
recent analysis pointed out that there are no drugswithmeasurable
teratogenic potential in the list of the 200 most prescribed drugs in
the USA [17].
After a complete examination of the child and a review of the
genetic and teratology medical literature, the clinician must decide
on whether the child’s malformations are due to a genetic cause or
an environmental toxin or agent (Boxes 1 and 2; Table 1). The
clinicianmay not be able to conclude, deﬁnitively or presumptively,
the etiology of the child’s birth defects. This information must then
be conveyed to the patient in an objective and compassionate
manner. A similar situation exists if a pregnant woman has been
exposed to a drug, chemical or physical agent, since themother will
want to know the risk of that exposure to her unborn child. If one
wishes to answer the generic question, ‘Is a particular environ-
mental drug, chemical or physical agent a reproductive toxicant?’
then a formal approach is recommended that includes a ﬁve-part
evaluation as described in Box 4.
5. Deﬁciencies in counseling education and methodology
Some physicians and other health professionals misinform their
patients regarding the magnitude of the risk of environmental
toxicant exposure during pregnancy [23,29]. Ratnapalan et al. [29]
surveyed a large number of general physicians and obstetricians
regarding the risk of abdominal computed tomography (CT) scan to
pregnant women during the 6th week of gestation (Table 4).
Experienced counselors understand that their primary task is to
educate the pregnant women or family members concerning the
risk of an environmental exposure. The counselor should advise
Table 1
Developmental toxicants: risks of congenital malformations and abortion in the human.
Developmental
toxicant
Reported effects or associations and estimated risks Commentsa
Alcohol Fetal alcohol syndrome: intrauterine growth retardation, maxillary hypoplasia, reduction in width
of palpebral ﬁssures, characteristic but not diagnostic facial features, microcephaly, mental
retardation. An increase in spontaneous abortion has been reported but since mothers who abuse
alcohol during pregnancy have multiple other risk factors, it is difﬁcult to determine whether this is
a direct effect on the embryo. Consumption of 6 oz of alcohol or more per day constitutes a high risk
but it is likely that detrimental effects can occur at lower exposures.
Quality of available information: good
to excellent.
Direct cytotoxic effects of ethanol and
indirect effects of alcoholism. Whereas
a threshold teratogenic dose is likely it
will vary in individuals because of a
multiplicity of factors.
Aminopterin,
methotrexate
Microcephaly, hydrocephaly, cleft palate, meningomyelocele, intrauterine growth retardation,
abnormal cranial ossiﬁcation, reduction in derivatives of ﬁrst branchial arch, mental retardation,
postnatal growth retardation. Aminopterin can induce abortion within its therapeutic range; it is
used for this purpose to eliminate ectopic embryos. Risk from therapeutic doses is unknown but
appears to be moderate to high.
Quality of available information: good.
Anticancer, antimetabolic agents; folic
acid antagonists that inhibit
dihydrofolate reductase, resulting in
cell death.
Androgens Masculinization of female embryo: clitoromegaly with or without fusion of labia minora. Non-
genital malformations are not a reported risk. Androgen exposures which result in masculinization
have little potential for inducing abortion. Based on animal studies, behavioral masculinization of
the female human will be rare.
Quality of available information: good.
Effects are dose and stage dependent;
stimulates growth and differentiation of
sex steroid receptor-containing tissue.
Angiotensin-converting
enzyme (ACE)
inhibitors
The therapeutic use of ACE inhibitors has neither a teratogenic effect nor an abortigenic effect in the
ﬁrst trimester. Since this group of drugs does not interfere with organogenesis, they can be used in a
woman of reproductive age; if the woman becomes pregnant, therapy can be changed during the
ﬁrst trimester without an increase in the risk of teratogenesis. Later in gestation these drugs can
result in fetal and neonatal death, oligohydramnios, pulmonary hypoplasia, neonatal anuria,
intrauterine growth retardation, and skull hypoplasia. Risk is dependent on dose and length of
exposure.
Quality of available information: good.
Antihypertensive agents; adverse fetal
effects are related to severe fetal
hypotension over a long period of time
during the second or third trimester.
Caffeine Caffeine is teratogenic in rodent species with doses of 150 mg/kg. There are no convincing data that
moderate or usual exposures (300 mg per day or less) present a measurable risk in the human for
any malformation or group of malformations. On the other hand, excessive caffeine consumption
(exceeding 300 mg per day) during pregnancy is associated with growth retardation and embryonic
loss.
Quality of available information: fair to
good.
Behavioral effects have been reported
and appear to be transient or
temporary; more information is needed
concerning the population with higher
exposures.
Carbamazepine Minor craniofacial defects (upslanting palpebral ﬁssures, epicanthal folds, short nose with long
philtrum), ﬁngernail hypoplasia, and developmental delay. Teratogenic risk is not known but likely
to be signiﬁcant for minor defects. There are too few data to determine whether carbamazepine
presents an increased risk for abortion. Since embryos with multiple malformations are more likely
to abort, it would appear that carbamazepine presents little risk because an increase in these types
of malformations has not been reported.
Quality of available information: fair to
good.
Anticonvulsant; little is known
concerning mechanism. Epilepsy may
itself contribute to an increased risk for
fetal anomalies.
Cocaine Preterm delivery; fetal loss; placental abruption; intrauterine growth retardation; microcephaly;
neurobehavioral abnormalities; vascular disruptive phenomena resulting in limb amputation,
cerebral infarctions and certain types of visceral and urinary tract malformations. There are few data
to indicate that cocaine increases the risk of ﬁrst trimester abortion. The low but increased risk of
vascular disruptive phenomena due to vascular compromise of the pregnant uterus would more
likely result in mid-gestation abortion or stillbirth. It is possible that higher doses could result in
early abortion. Risk for deleterious effects on fetal outcome is signiﬁcant; risk for major disruptive
effects is low, but can occur in the latter portion of the ﬁrst trimester as well as the second and third
trimesters.
Quality of available information: fair to
good.
Cocaine causes a complex pattern of
cardiovascular effects due to its local
anesthetic and sympathomimetic
activities in the mother. Fetopathology
is likely to be due to decreased uterine
blood ﬂow and fetal vascular effects.
Because of the mechanism of cocaine
teratogenicity, a well-deﬁned cocaine
syndrome is not likely. Poor nutrition
accompanies drug abuse and multiple
drug abuse is common.
Chorionic villous
sampling (CVS)
Low, but increased risk of orofacial malformations and limb reduction defects of the congenital
amputation type as seen in vascular disruption malformations in some series. The risk of abortion
following CVS is quite low.
Quality of available information: fair.
Excessive bleeding from the chorion is
probably related in part to the
experience of the operator. Further
research is necessary to determine
whether CVS is safer for the fetus at
certain stages of gestation.
Coumarin derivatives Nasal hypoplasia; stippling of secondary epiphysis; intrauterine growth retardation; anomalies of
eyes, hands, neck; variable central nervous system anatomical defects (absent corpus callosum,
hydrocephalus, asymmetrical brain hypoplasia). Risk from exposure 10e25% during 8th to 14th
week of gestation. There is also an increased risk of pregnancy loss. There is a risk to the mother and
fetus from bleeding at the time of labor and delivery.
Quality of available information: good.
Anticoagulant; bleeding is an unlikely
explanation for effects produced in the
ﬁrst trimester. Central nervous system
defects may occur any time during
second and third trimesters and may be
related to bleeding.
Cyclophosphamide Growth retardation, ectrodactyly, syndactyly, cardiovascular anomalies, and other minor anomalies.
Teratogenic risk appears to be increased but the magnitude of the risk is uncertain. Almost all
chemotherapeutic agents have the potential for inducing abortion. This risk is dose-related; at the
lowest therapeutic doses the risk is small.
Quality of available information: fair.
Anticancer, alkylating agent; requires
cytochrome P450 mono-oxidase
activation; interacts with DNA,
resulting in cell death.
Diethylstilbestrol (DES) Clear cell adenocarcinoma of the vagina occurs in about 1:1000 to 10 000 females whowere exposed
in utero. Vaginal adenosis occurs in about 75% of females exposed in utero before the 9th week of
pregnancy. Anomalies of the uterus and cervixmay play a role in decreased fertility and an increased
incidence of prematurity although the majority of women exposed to DES in utero can conceive and
deliver normal babies. In-utero exposure to DES increased the incidence of genitourinary lesions and
Quality of available information: fair to
good.
Synthetic estrogen; stimulates estrogen
receptor-containing tissue, may cause
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Table 1 (continued )
Developmental
toxicant
Reported effects or associations and estimated risks Commentsa
infertility in males. DES can interfere with zygote survival, but it does not interfere with embryonic
survival when given in its usual dosage after implantation. Offspring who were exposed to DES in
utero have an increased risk for delivering prematurely, but do not appear to be at increased risk for
ﬁrst trimester abortion.
misplaced genital tissue which has a
greater propensity to develop cancer.
Diphenylhydantoin Hydantoin syndrome: microcephaly, mental retardation, cleft lip/palate, hypoplastic nails and distal
phalanges; characteristic but not diagnostic facial features. Associations documented only with
chronic exposure. Wide variation in reported risk of malformations but appears to be10%. The few
epidemiological data indicate a small risk of abortion for therapeutic exposures for the treatment of
epilepsy. For short-term treatment, i.e. prophylactic therapy for a head injury, there is no
appreciable risk.
Quality of available information:
fair to good.
Anticonvulsant; direct effect on cell
membranes, folate, and vitamin K
metabolism. Metabolic intermediate
(epoxide) has been suggested as the
teratogenic agent.
Electromagnetic
ﬁelds (EMFs)
The data pertaining to video display terminals indicate that the EMF exposures from these units do
not present an increased risk for abortion or congenital malformations. The data on power line and
appliance exposures are too varied to draw any conclusions, although the risks appear to be small or
non-existent. Human exposures to video display terminals and power lines are quite low and are
unlikely to have reproductive effects.
Quality of available information: fair.
Pregnant animals exposed to EMF do
not exhibit consistent or reproducible
reproductive effects. There are still
questions about biologic effects for
frequencies and wave forms of
magnetic ﬁelds that have not been
adequately studied.
Fluconazole Fluconazole, a triazole antifungal agent used to treat mycotic infections, is a widely administered
medication for vaginal candidiasis. In this latter treatment, it is prescribed as a single dose of 150mg
and has not been associated with increased abnormalities or congenital defects in pregnancy series
[18e20] Fluconazole is also used to treat more serious mycotic infections at doses of 400e800 mg/
day on a continuous basis. During the 1990s, four case reports of infants exposed to this high-dose
regimen of ﬂuconazole had a distinct and consistent pattern of malformations [21] The constellation
of defects consisted of craniosynostosis, orbital hypoplasia, and the rather unique skeletal
manifestations of humeral radial synostosis and femoral bowing.
Quality of available information: fair.
Infectious agents The cytotoxic effects and inﬂammatory responses resulting from fetal infections interfere with
organogenesis and/or histogenesis. Fetopathic syndromes are related to the speciﬁc tissue
localization, pathologic characteristics of the infectious agent and the duration of the infection in the
embryo and fetus. In some instances the infection may be debilitating to the mother and indirectly
result in pregnancy loss.
Cytomegalovirus (CMV) Fetal cytomegalovirus infection presents an increased risk for abortion but it does not appear that
maternal genital infection increases the risk of abortion. Fetal infection occurs in about 20% of
maternal infections. Intrauterine growth retardation: risk of brain damage is moderate after fetal
infection early in pregnancy; characteristic parenchymal calciﬁcation.
Quality of available information: good
to excellent.
CMV damages organs principally by
cellular necrosis.
Herpes simplex virus Generalized organ infections, microcephaly, hepatitis, eye defects, vesicular rash. Maternal infection
can be transmitted in utero or perinatally. Herpes simplex 2 is one of the few infections where it is
agreed that the risk of abortion is increased.
Quality of available information: good.
Fetal anomalies associated with herpes
simplex virus infection appear to be due
to disruption rather than malformation.
Human
immunodeﬁciency
virus (HIV)
The overall risk of vertical transmission of HIV is 25e40%. Fetal HIV infection and asymptomatic
maternal HIV infection are not associated with adverse effect on fetal growth or development.
Symptomatic maternal HIV infection, other sexually transmitted diseases and opportunistic
infections may increase the risk of low birth weight or perinatal morbidity.
Quality of available information: fair to
good.
Prophylactic treatment with zidovudine
does not appear to cause permanent
adverse effects in the fetus.
Parvovirus B19 Infection can result in erythema infectiosum in children but in the fetus can result in hydrops fetalis
and fetal death; congenital anomalies are likely to be very rare. The risk for stillbirth with hydrops
has been clearly substantiated. An increased risk for abortion has been suggested, but is more
difﬁcult to substantiate.
Quality of available information: fair to
good.
Fetal infection is not frequent. Infection
of red blood cell precursors causes
severe anemia.
Rubella virus Greater than 80% incidence of embryonic infection with exposure in ﬁrst 12 weeks, 54% at 13e14
weeks, 25% at end of second trimester, and 100% at term. Defects include mental retardation,
deafness, cardiovascular malformations, cataracts, glaucoma, microphthalmia. Diabetes mellitus or
rubella panencephalitis may develop later in life. The abortigenic risk of maternal rubella is
uncertain.
Quality of available information:
excellent.
Rubella has an afﬁnity for speciﬁc
tissues. Damage is caused by mitotic
inhibition, cell death and interference
with histogenesis by repair processes,
resulting in calciﬁcation and scarring.
Syphilis Defects in 50% of offspring after early exposure to primary or secondary syphilis and 10% after late
exposures. Defects include maculopapular rash, hepatosplenomegaly, deformed nails,
osteochondritis at joints of extremities, congenital neurosyphilis, abnormal epiphyses,
chorioretinitis. Syphilis can increase the incidence of abortion.
Quality of available information: good.
Fetal pathology is associated with
maturation of the fetal immune system
at about the 20th week.
Toxoplasmosis Hydrocephaly, microphthalmia, chorioretinitis. Risk is predominantly associated with pregnancies
in which the mother acquires toxoplasmosis. Epidemiological studies do not indicate that
toxoplasmosis increases the incidence of early abortion, but congenital toxoplasmosis may be
responsible for the stillbirth of severely affected fetuses.
Quality of available information: good
to excellent.
Toxoplasmosis is unlikely to contribute
to the risk of repeated abortion.
Varicella-zoster Skin and muscle defects; intrauterine growth retardation; limb reduction defects. No measurable
increased risk of early teratogenic effects. Incidence of maternal varicella during pregnancy is low
but risk of severe neonatal infection is high if maternal infection occurs in last week of pregnancy.
There does not appear to be an increased risk of ﬁrst trimester abortion.
Quality of available information: fair to
good.
Virus infection of fetal tissues can cause
cellular necrosis.
Venezuelan equine
encephalitis
Hydroencephaly; microphthalmia; central nervous system destructive lesions; luxation of hip.
There are not enough data to determine whether infection presents an increased risk of abortion.
Quality of available information: poor
to fair.
Infection can cause cellular necrosis in
fetal tissues but fetal infection is rare.
(continued on next page)
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Developmental
toxicant
Reported effects or associations and estimated risks Commentsa
Lead There is no indication that serum lead levels<50 mg% result in congenital malformations in exposed
embryos and fetuses but the developing central nervous system in the fetus and child may be
susceptible to lead toxicity, resulting in decreased IQ and behavioral effects. Lead levels >50 mg%
result in anemia, and encephalopathy can have serious effects on central nervous system
development. Lead levels <50 mg% do not increase the risk of abortion.
Quality of available information: good.
Whereas there are human studies
indicating small deﬁciencies in IQ in
patients with lead levels >10 mg%, there
could be other explanations for these IQ
differences. Furthermore, pathological
ﬁndings have not been described in the
brain at these levels.
Lithium carbonate Although animal studies have demonstrated a clear teratogenic risk, the effect in humans is
uncertain. Early reports indicated an increased incidence of Ebstein’s anomaly, other heart and great
vessel defects, but as more studies are reported the strength of this association has diminished.
Lithium levels within the therapeutic range (<1.2 mg%) do not increase the risk of abortion.
Quality of available information: fair to
good.
Antidepressant; mechanism has not
been deﬁned.
Maternal conditions
Diabetes Caudal hypoplasia or caudal regression syndrome; congenital heart disease; anencephaly. Vascular
lesions in long-standing diabetics may produce placental dysfunction and result in fetal growth
retardation. Documented signiﬁcant increased risk of abortion. The risk is greatest in untreated
diabetics or in patients who are poorly controlled; insulin therapy protects the fetus.
Quality of available information: good.
Results of in-vitro studies suggest that
diabetic embryopathy has a
multifactorial etiology. Adverse fetal
effects have not been demonstrated
with gestational diabetes.
Endocrinopathy If condition is compatible with pregnancy, effects are similar to those following administration of
high or low doses of the hormone. Hypo- and hyperthyroidism may increase the risk of abortion.
Cushing’s disease, pituitary tumors, hypothalamic tumors and androgen-producing tumors do not
appear to increase the risk of abortion, but may contribute to infertility.
Quality of available information: good.
Receptor-mediated exposures to high
levels of hormone.
Nutritional deprivation Central nervous system anomalies; intrauterine growth restriction; increased morbidity. In some
instances of teratogenesis, abnormal nutrition may be the ﬁnal common mechanism. Severe
malnutrition can contribute to pregnancy loss at any stage of pregnancy.
Quality of available information: fair to
good.
The high mitotic rate of the fetus in
general and the central nervous system
in particular is very sensitive to severe
alterations in nutrient supply.
Phenylketonuria Mental retardation; microcephaly; intrauterine growth retardation. Documented signiﬁcant
increased risk of abortion. The risk is greatest in pregnant women who were not treated for their
phenylketonuria.
Quality of available information: good.
Very high levels of phenylalanine
interfere with embryonic cell
metabolism.
Mechanical problems Birth defects such as club feet, limb reduction defects, aplasia cutis, cranial asymmetry, external ear
malformations, midline closure defects, cleft palate and muscle aplasia. Submucosal and intramural
myomata, amniotic bands, multiple implantations, biﬁd uterus or infantile uterus which contribute
to mechanical problems do not result in early abortions.
Quality of available information: good.
Physical constraint can result in
distortion and a reduction in blood
supply and is more frequent in
pregnancies with multiple conceptuses,
abnormal uterus, amniotic
abnormalities, certain placental
abnormalities and oligohydramnios.
Methyl mercury Minamata disease: cerebral palsy, microcephaly, mental retardation, blindness, cerebellar
hypoplasia. Does not appear to decrease fertility unless the mother becomes clinically ill from
methyl mercury poisoning. At low exposures the teratogenic effect predominates and there are few
human data to indicate the risk of abortion.
Quality of available information: good.
Organic mercurials accumulate in lipid
tissue causing cell death due to
inhibition of cellular enzymes,
especially sulfhydryl enzymes. Since
most cases result from accidental
environmental exposure, risk
estimation is usually retrospective.
Methylene blue Hemolytic anemia and jaundice in neonatal period after exposure late in pregnancy. There may be a
small risk for intestinal atresia but this is not yet clear. No indication of increased risk of abortion.
Quality of available information: poor
to fair.
Used to mark amniotic cavity during
amniocentesis.
Misoprostol Misoprostol is a synthetic prostaglandin analog that has been used by millions of women for illegal
abortion. A low incidence of vascular disruptive phenomenon, such as limb reduction defects and
Moebius syndrome, has been reported.
Quality of available information: fair.
Classical animal teratology studies
would not be helpful in discovering
these effects, because vascular
disruptive effects occur after the period
of early organogenesis.
Mycophenolate mofetil This drug is a highly efﬁcient immunosuppressant used to prevent organ rejection after organ
transplantation. The agent, which blocks purine synthesis in lymphocytes, raised deﬁnite concern
when congenital defects were reported to the National Transplantation Pregnancy Registry: three
infants all exposed through the ﬁrst trimster exhibited congenital malformations, two with cleft lip
with cleft palate, and all three with microtia; one of the infants had a diaphragmatic defect, a
malformation seen in rats and rabbits treated with mycophenolate mofetil.
Quality of the data: fair.
Investigators raise concerns regarding
teratogenicity.
Oxazolidine-2,4-diones
(trimethadione,
paramethadione)
Fetal trimethadione syndrome: V-shaped eye brows, low-set ears with anteriorly folded helix, high-
arched palate, irregular teeth, CNS anomalies, severe developmental delay. Wide variation in
reported risk. Characteristic facial features are documented only with chronic exposure. The
abortifacient potential has not been adequately studied, but appears to be minimal.
Quality of available information: good
to excellent.
Anticonvulsants; affects cell membrane
permeability. Actual mechanism of
action has not been determined.
D-Penicillamine Cutis laxa, hyperﬂexibility of joints. Condition appears to be reversible and the risk is low. There are
no human data on the risk of abortion.
Quality of available information: fair to
good.
Copper chelating agent; produces
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Table 1 (continued )
Developmental
toxicant
Reported effects or associations and estimated risks Commentsa
copper deﬁciency inhibiting collagen
synthesis and maturation.
Polychlorinated
biphenyls
Cola-colored babies: pigmentation of gums, nails and groin; hypoplastic deformed nails;
intrauterine growth retardation; abnormal skull calciﬁcation. Although abortion can be induced at
high exposures, most human exposures from environmental contamination are unlikely to increase
the risk of abortion.
Quality of available information: good.
Environmental contaminants;
polychlorinated biphenyls and
frequently occurring contaminants are
cytotoxic. Body residues in exposed
women can affect pigmentation in
offspring for up to 4 years after
exposure.
Progestins Masculinization of female embryo exposed to high doses of some testosterone-derived progestins
and may interact with progesterone receptors in the liver and brain later in gestation. The dose of
progestins present in modern oral contraceptives presents no masculinization or feminization risks.
All progestins present no risk for non-genital malformations. Many synthetic progestins and natural
progesterone have been used to treat luteal phase deﬁciency, embryos implanted via in-vitro
fertilization, threatened abortion or bleeding in pregnancy with variable results. Conversely,
synthetic progestins that interfere with progesterone function may cause early pregnancy loss; RU-
486 (mifepristone) is presently used speciﬁcally for this purpose.
Quality of available information: good.
Stimulates or interferes with sex steroid
receptor-containing tissue.
Radioactive isotopes Tissue- and organ-speciﬁc damage is dependent on the radioisotope element and distribution, i.e.
131I administered to a pregnant woman can cause fetal thyroid hypoplasia after the 8th week of
development. Radioisotopes used for diagnosis present no risk for inducing abortion because the
dose to the embryo and implantation site is too low. There may be unusual circumstances wherein
isotopes are introduced into the abdominal cavity in a pregnant woman for the treatment of
malignancy. If the resulting dose to the embryo or fetus is substantial, the risk for abortion is
increased.
Quality of available information: good
to excellent.
Higher doses of radioisotopes can
produce cell death and mitotic delay.
Effect is dependent on dose,
distribution, metabolism, and
speciﬁcity of localization.
Radiation
(external irradiation)
Microcephaly; mental retardation; eye anomalies; intrauterine growth retardation; visceral
malformations. Teratogenic risk depends on dose and stage of exposure. Exposures from diagnostic
procedures present no increased risk of abortion, growth retardation or malformation. No
measurable risk with exposures for5 rad (5mGy) of X-rays at any stage of pregnancy. In contrast,
exposure of the pregnant uterus to therapeutic doses of ionizing radiation signiﬁcantly increases the
risk of aborting the embryo; the fetus is more resistant.
Quality of available information: good
to excellent.
Diagnostic and therapeutic agents;
produce cell death and mitotic delay.
Retinoids, systemic
(isotretinoin,
etrentinate)
Increased risk of central nervous system, cardio-aortic, ear and clefting defects. Microtia, anotia,
thymic aplasia and other branchial arch, aortic arch abnormalities and certain congenital heart
malformations. Exposed embryos are at greater risk for abortion. This is plausible since many of the
malformations, such as neural tube defects, are associated with an increased risk of abortion.
Quality of available information: fair.
Used in treatment of chronic
dermatoses. Retinoids can cause direct
cytotoxicity and alter programmed cell
death; affect many cell types but neural
crest cells are particularly sensitive.
Retinoids, topical
(tretinoin)
Epidemiological studies, animal studies and absorption studies in humans do not suggest a
teratogenic risk. Regardless of the risks associated with systemically administered retinoids, topical
retinoids present little or no risk for intrauterine growth retardation, teratogenesis or abortion
because they are minimally absorbed and only a small percentage of skin is exposed.
Quality of available information: poor.
Topical administration of tretinoin in
animals in therapeutic doses is not
teratogenic, although massive
exposures can produce maternal
toxicity and reproductive effects. More
importantly, topical administration in
humans results in non-measurable
blood levels.
Smoking and nicotine Placental lesions; intrauterine growth retardation; increased postnatal morbidity and mortality.
While there have been some studies reporting increases in anatomical malformations, most studies
do not report an association. There is no syndrome associated with maternal smoking. Maternal or
placental complications can result in fetal death. Exposures to nicotine and tobacco smoke are a
signiﬁcant risk for pregnancy loss in the ﬁrst and second trimester.
Quality of available information: good
to excellent.
While tobacco smoke contains many
components, nicotine can result in
vascular spasm vasculitis which has
resulted in a higher incidence of
placental pathology.
Sonography
(ultrasound)
No conﬁrmed detrimental effects resulting from medical sonography. The levels and types of
medical sonography that have been used in the past have no measurable risks. The present clinical
use of diagnostic ultrasound presents no increased risk of abortion.
Quality of available information: good
to excellent.
It appears that if the embryonic
temperature never exceeds 39 C, there
is no measurable risk.
Streptomycin Streptomycin and a group of ototoxic drugs can affect the eighth nerve and interfere with hearing; it
is a relatively low risk phenomenon. There are not enough data to estimate the abortigenic potential
of streptomycin. Because the deleterious effect of streptomycin is limited to the eighth nerve, it is
unlikely to affect the incidence of abortion.
Quality of available information: fair to
good.
Long-duration maternal therapy during
pregnancy is associated with hearing
deﬁciency in offspring.
Tetracycline Bone staining and tooth staining can occur with therapeutic doses. Persistent high doses can cause
hypoplastic tooth enamel. No other congenital malformations are at increased risk. The usual
therapeutic doses present no increased risk of abortion to the embryo or fetus.
Quality of available information: good.
Antibiotic; effects seen only if exposure
is late in the ﬁrst or during second or
third trimester, since tetracyclines have
to interact with calciﬁed tissue.
Thalidomide Limb reduction defects (preaxial preferential effects, phocomelia), facial hemangioma, esophageal or
duodenal atresia, anomalies of external ears, eyes, kidneys, and heart, increased incidence of
neonatal and infant mortality. The thalidomide syndrome, although characteristic and recognizable,
can be mimicked by some genetic diseases. Although there are fewer data pertaining to its
abortigenic potential, there appears to be an increased risk of abortion.
Quality of available information: good
to excellent.
Sedativeehypnotic agent. The etiology
of thalidomide teratogenesis has not
been deﬁnitively determined.
(continued on next page)
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Table 1 (continued )
Developmental
toxicant
Reported effects or associations and estimated risks Commentsa
Thyroid: iodides,
radioiodine,
antithyroid drugs
(propylthiouracil),
iodine deﬁciency
Fetal hypothyroidism or goiter with variable neurologic and aural damage. Maternal
hypothyroidism is associated with an increase in infertility and abortion. Maternal intake of12 mg
of iodide per day increases the risk of fetal goiter.
Quality of available information: good.
Fetopathic effect of endemic iodine
deﬁciency occurs early in development.
Fetopathic effect of iodides, antithyroid
drugs and radio iodine involves
metabolic block, decreased thyroid
hormone synthesis and gland
development.
Toluene Intrauterine growth retardation; craniofacial anomalies; microcephaly. It is likely that high
exposures from abuse or intoxication increase the risk of teratogenesis and abortion. Occupational
exposures should present no increase in the teratogenic or abortigenic risk. The magnitude of the
increased risk for teratogenesis and abortion in abusers is not known because the exposure in
abusers is too variable.
Quality of available information: poor
to fair.
Neurotoxicity is produced in adults who
abuse toluene; a similar effect may
occur in the fetus.
Valproic acid Malformations are primarily neural tube defects and facial dysmorphology. The facial characteristics
associated with this drug are not diagnostic. Small head size and developmental delay have been
reported with high doses. The risk for spina biﬁda is about 1% but the risk for facial dysmorphology
may be greater. Because therapeutic exposures increase the incidence of neural tube defects, one
would expect a slight increase in the incidence of abortion.
Quality of available information: good.
Anticonvulsant; little is known about
the teratogenic action of valproic acid.
Vitamin A The same malformations that have been reported with the retinoids have been reported with very
high doses of vitamin A (retinol). Exposures <10 000 IU present no risk to the fetus. Vitamin A in its
recommended dose presents no increased risk for abortion.
Quality of available information: good.
High concentrations of retinoic acid are
cytotoxic; it may interact with DNA to
delay differentiation and/or inhibit
protein synthesis.
Vitamin D Large doses given in vitamin D prophylaxis are possibly involved in the etiology of supravalvular
aortic stenosis, elﬁn faces, and mental retardation. There are no data on the abortigenic effect of
vitamin D.
Quality of available information: poor.
Mechanism is likely to involve a
disruption of cell calcium regulation
with excessive doses.
a Quality of available information is modiﬁed from TERIS [22].
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the contrary, in one survey, up to 6% of all physicians would
recommendmedical termination of pregnancy for womenwho had
undergone a single CT at 6 weeks of gestation and 27% of all phy-
sicians surveyed were uncertain if they would recommend a
medical termination of pregnancy (Box 2) [29]. In case of a toxi-
cological exposure, the counselor should attempt to establish a
good understanding of the exposure in question and its timing. A
list of information required to provide high quality counseling to
those exposed is listed in Boxes 1 and 3. The pervasive problem is
that many physicians and counselors tell the patient or family what
to do. In many instances the counselor (i) has no expertise con-
cerning the risks of an exposure, or (ii) the counselor knows the
risks, but he/she does not take the time to educate the patient about
the risks.
6. Counseling: What are the reproductive or developmental
concerns of pregnant women and/or family members
concerning the risk of alleged or suspected toxicological
exposures during pregnancy or before pregnancy? Role of the
counselor
These concerns include (i) birth defects (congenital malforma-
tions), (ii) pregnancy loss (miscarriage or spontaneous abortion),
(iii) growth retardation, (iv) prematurity, (v) neurobehavioral ef-
fects (decreased IQ, small head size, convulsive disorders, autism,
attention deﬁcit hyperactivity disorder) and cancer. All of these
effects except for cancer and mutations in the F1 generation are
deterministic effects (threshold effects, tissue reaction effects)
(Table 5). The term ‘tissue reaction’ effects is a new term adopted
because it conveys the concept that these effects involve exposure
to tissues indicating that many cells have to be affected, which
explains why there is a threshold belowwhich there is no increased
risk (Table 5).
Mutagens have the potential to induce cancer or genetic effects
by altering one cell, and therefore theoretically do not have a
threshold [20e44]. Recent discussions of the universal applicationof the linear-no-threshold hypothesis (LNTH) indicate that there is
disagreement as to whether the LNTH is applicable at very low
exposures to environmental toxicants and with protracted toxicant
exposures (Table 5) [35e37].
7. The role of the counselor
The classical approach for the evaluation of risks from in-utero
environmental exposures is to review the available epidemiolog-
ical studies and appropriate animal models, and to evaluate these
data from the standpoint of biologic plausibility or biologic common
sense (Box 4) [26]. In order to perform an analysis outlined in Box 4,
the drug, chemical or physical agent has to have been distributed or
sold for a period of years so that epidemiological data, animal toxi-
cology data and in-vitro studies are available for analysis.
7.1. Evaluating the allegation of teratogenicity
When confronted with the question of the teratogenicity of
certain environmental agents, the question can be posed from
various vantage points:
1. Evaluating the risk of reproductive toxicity of an environmental
agent.
2. Evaluating the suggestion that an environmental agent was
responsible for an individual child’s birth defect or other
reproductive effects.
3. Evaluating the cause of congenital malformations in a particular
child or a group of children.
4. Determining whether to publish a case report of a patient or a
cluster of patients with a particular congenital malformation or
a constellation of congenital malformations that may be asso-
ciated with an environmental agent [38].
If one wishes to answer the generic question, ‘Is a particular
environmental drug, chemical or physical agent a reproductive
toxicant?’, then a formal approach is recommended that includes a
Box 2
Responsibilities of the counselor.
1. Questions submitted by patients or contacts regarding
environmental toxicant exposures should never be
described as silly, dumb or unnecessary. Every response
should attempt to dignify the question as appropriate.
However, the counselor should provide scientific expla-
nations as to why the contact’s concerns are or are not
substantiated by the available facts. The counselor is an
educator.
2. It is difficult for many counselors to comprehend the
anguish, heartache, fear and concern in the hearts and
minds of the contacts when they are concerned about the
health of their fetus from exposures to environmental
toxicants. The degree of fear is related to themental state
of the contact as well as the type and magnitude of the
exposure to the environmental toxicant.
3. Many counselors do not understand that their profes-
sional goal should be to educate the contact about the
reproductive or developmental risks that may result from
a particular environmental exposure, not to advise them
what decision they should select.
4. Many novice counselors do not realize that it is their re-
sponsibility to provide the contacts with the background
risk that they face, evenwhen there are no increased risks
from the exposure. The contacts are requested to keep
the counselor informed. Do they have any more ques-
tions? Please keep in touch, send a picture. The consul-
tation is signed with ‘Warm regards’. It should be made
clear to the contact that the counselor has functioned as
an educator. The counselor does not advise contacts on
what decision to select, only the options that are avail-
able. Yet, many contacts thank the counselor for telling
them what to do, even though they have not been
advised on which available option to select.
5. It is important to permanently save a written record of the
statements of the contact and the counselor.
6. Each consultation that definitively determined that their
reproductive or developmental risks are not increased
ends with this statement:
‘Your risk for birth defects or miscarriage is not
increased above the background risks that all healthy
pregnant women face. The background risks for preg-
nant women with no personal or family history of
reproductive or developmental problems is 3% for
birth defects and 15% for miscarriage. All pregnant
women face these risks, many of which we cannot yet
prevent.’
We wish them good luck with their pregnancy and to
keep in touch. If the contact asks about the risks of
mental retardation, cancer or other effects, these
background risks are discussed also. The answers are
directed specifically to their questions.
If the contact is concerned about cancer in her
offspring from either preconception or postconception
exposures, it is most important to educate the contact
regarding the high background incidence of cancer in
the population. Potentially lethal cancers occur in 23%
of the population, which dwarfs the incidence of envi-
ronmentally induced cancer. It is important to point out
that the spontaneous occurrence of cancer, which in-
creases with age due to mutation that occurs in the
dividing somatic cells, is the most important etiology
of human cancer.
Box 3
Minimum information required to provide adequate counseling
to women or couples regarding concerns about the risks of
environmental toxicant exposures before or during the
pregnancy.a
1. Is the contact pregnant, possibly pregnant or planning to
become pregnant?
2. If the contact is pregnant, does she know the date she
became pregnant? Does she know the date of the first
day of her last menstrual period?
3. Does she know the date of conception from other sour-
ces: an ultrasound that timed the pregnancy or a date
when intercourse took place that is consistent with other
information about timing?
4. Are there historical pregnancy risks (birth defects,
miscarriage, etc.) for the mother or the family e for
example, a history of miscarriages, birth defects, infer-
tility or serious illnesses in the contact, spouse, or par-
ents or siblings?
5. Does the contact know the name of the environmental
toxicant to which she or her spouse was exposed? Is it a
drug, chemical or physical agent (such as radiation or
heat)? What was the amount and length of the exposure
before or during pregnancy? Provide the dates and
amount (dose) of the exposure. The Environmental Pro-
tection Agency (EPA) has prepared toxicological evalu-
ations of chemicals using animal studies and now high-
throughput in-vitro studies. The EPA may even have
estimated a reference dose exposure, which is an expo-
sure that has no deterministic reproductive effects.
6. Has the woman or couple sought advice from another
counselor about the developmental risks of this expo-
sure? Please provide details of the response.
7. The needs of the person seeking counseling are the only
operative issues to be considered.
aAdapted from Brent [23].
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approach is utilized only when a drug or chemical has been utilized
and sold for a period of many years and, during that time, studies on
epidemiology, animals and pharmacokinetics have been performed
[30e37].
If, on the other hand, one is concerned about the reproductive
effects of an environmental agent in an individual patient, the
question may sometimes be answered without the beneﬁt of
epidemiological studies, dosimetry or animal studies, utilizing the
basic principles of teratology, reproductive toxicology and genetics.
Key factors in such an evaluation are having an experienced clini-
cian who is knowledgeable about the genocopies that can mimic
environmental teratogens, who is aware of the importance of dose
or exposure and who is aware of the basic principles of develop-
mental biology and teratology. A clinician trained and experienced
in these ﬁelds may have a decisive role in utilizing the principles of
teratology (Box 1) and biological plausibility in evaluating the
allegation that a particular environmental agent was responsible
for a child’s congenital malformations [10,28,38e40,42,44,45,52].7.2. Counselors must have knowledge of known or possible
reproductive toxins
Reproductive and developmental counselors should have been
educated and prepared to discuss background risks of birth defects
and the broad subject of the etiology of developmental birth defects
Table 2
Etiology of human congenital malformations.a
Suspected cause Percent of total
Unknown 65
Polygenic
Multifactorial (geneeenvironment interactions)
Spontaneous errors of development
Synergistic interactions of teratogens
Genetic 15e25
Autosomal and sex-linked inherited genetic disease
Cytogenetic (chromosomal abnormalities)
New mutations
Environmental (total) 10
Maternal conditions: alcoholism; diabetes;
endocrinopathies; phenylketonuria; smoking and
nicotine; starvation; nutritional deﬁcits
4
Infectious agents: rubella, toxoplasmosis, syphilis,
herpes simplex, cytomegalovirus, varicella-zoster,
Venezuelan equine encephalitis, parvovirus B19
3
Mechanical problems (deformations): amniotic band
constrictions; umbilical cord constraint; disparity in
uterine size and uterine contents
1e2
Chemicals, prescription drugs, high-dose ionizing
radiation, hyperthermia
2
a Source: Brent [9].
Box 4
Evaluation of potential for developmental toxicity in the human:
evidence of a possible causal relationship.a
 Epidemiological studies
Controlled epidemiological studies consistently demon-
strate an increased incidence of a particular spectrum of
embryonic and/or fetal effects in exposed human
populations.
 Secular trend data
Secular trends demonstrate a positive relationship between
the changing exposures to a common environmental agent
in human populations and the incidence of a particular
embryonic and/or fetal effect.
 Animal developmental toxicity studies
An animal model can be developed which mimics the hu-
man developmental effect at clinically comparable expo-
sures. Since mimicry may not occur in all animal species,
animal models aremore likely to be developed once there is
good evidence for the embryotoxic effects reported in the
human. Developmental toxicity studies in animals are
indicative of a potential hazard in general rather than the
potential for a specific adverse effect on the fetus when
there are no human data on which to base the animal
experiments.
 Doseeresponse relationship
Developmental toxicity in humans increases with dose
(exposure) and the developmental toxicity in animals oc-
curs at a dose that is pharmacokinetically (quantitatively)
equivalent to the human exposure.
 Biological plausibility
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knowledge of known or possible reproductive toxins and be
familiar with how themedial literature dealing with teratogens can
be accessed [22,46e55].
Table 1 provides a list of known or alleged reproductive toxin or
teratogenic agents. The TERIS andOTISwebsites aremore up-to-date,
as is the genetic website of the National Library of Medicine (OMIM).
Each counselor may have many consultations in their ﬁles;
however, it is not the purpose of this publication to provide
numerous examples. On the Health Physics website, Ask the Expert
(ATE), there are more than 60 prototype questions. NCRP 174,
published in 2013 [52], has an appendix with scores of consultation
questions and answers that pertain to the preconception and
postconception risks of ionizing radiation, ultrasound, non-ionizing
electromagnetic ﬁelds, CT scans and magnetic resonance imaging.
A few examples of responses to contacts exposed to environ-
mental toxicants are presented below. A preconception and post-
conception toxicant exposure is discussed, as well as a contact whoTable 3
Reproductive risks per million recognized pregnancies.a
Reproductive risks Frequency
Immunologically and clinically diagnosed spontaneous
abortions per million conceptions (<20% has lethal
malformations or chromosome abnormalities that
cause abortion before the ﬁrst month of gestation).
350 000
Clinically recognized spontaneous abortions per million
clinically recognized pregnancies. Spontaneous
abortion after the ﬁrst missed menstrual period.
150 000
Genetic diseases per million births 110 000
Multifactoral or polygenic genetic environmental
interactions)
90 000
Dominantly inherited disease 10 000
Autosomal and sex-linked genetic disease 1200
Cytogenetic (chromosomal abnormalities) 5000
New mutations in the developing ova or sperm prior
to conception
3000
Major malformations (genetic, unknown, environmental) 30 000
Prematurity (Ireland: 55 000; USA: 124 000) 69 000
Fetal growth restriction 30 000
Stillbirths (>20 weeks; wide range in prevalence because
of variables contributed by cultures, socio-economic
factors, race, prenatal medical care)
4000e20 900
Infertility 7% of couples
a Source: Brent [9].
The mechanisms of developmental toxicity are understood
and the effects are biologically plausible.
aModified from Brent et al. [25], Brent [26,27], and Shepard
[28].is concerned about the etiology of the child’s birth defects. Another
frequently asked question pertains as towhether a cluster of similar
birth defects in a small geographic area is due to an environmental
toxicant.
(1) Preconception exposure: The father or the mother in the
family may have been exposed to a toxicological exposure before
the pregnancy has occurred. One of the future parents could have
been treated with radiation therapy or chemotherapy for cancer
that they survived; or one of the parents had multiple diagnostic X-
rays as a child or adolescent. The family is concerned about the
genetic effects of prior alleged toxicological mutagenic exposures at
home or at work. Of the thousands of consultations we have
received, about 20% are from future parents concerned about pre-
conception toxicological exposures. Some of the exposures have
occurred many years before they contemplated having a family.
Genetic studies of the offspring of patients exposed to muta-
genic agents are largely negative. However, we know that muta-
tions have been produced, but the risk of viable offspring with an
Table 4
Survey of obstetricians and family physicians from Ontario, Canada, on medical
termination of pregnancy in women who underwent radiography or computed to-
mography (CT) during early pregnancy.a
Medical termination of pregnancy
recommended
Percentage of respondents
Family physicians
(n ¼ 208)
Obstetricians
(n ¼ 65)
Radiography CT Radiography CT
Yes 1 6 0 5
Not sure 25 39 6 25
No 74 55 94 70
a Source: Ratnapalan et al. [29].
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would need very large populations of exposed individuals to
demonstrate the increased risk.
There is no convincingdirect evidence of germlinemutation seen
as heritable disease in the offspring of humans and attributable to
ionizing radiation and mutagenic chemicals and drugs, yet these
mutagens clearly inducemutations in microbes and somatic cells of
rodents and humans, and in offspring of exposed mice. It would be
unwise to ignore the possibility of human germ-cell mutations,
especially since progress in human genetics may be able to address
these issues in the future. Preconception exposure of the ovaries or
testes to toxicological agents or low exposure tomutagenic drugs or
chemicals is a very low risk phenomenon, especially for exposures
fromdiagnostic radiological procedures. There is no risk for sterility.
Since the vulnerable irradiated ova will have been ovulated in two
menstrual cycles (2 months) and the irradiated sperm replaced in
two spermatogenesis cycles (4months), it is best that the familywait
that period of time before attempting conception. If pregnancy oc-
curs during these windows of time, the environmental toxicant
mutagenic risks are miniscule (Box 3) compared with spontaneous
risk of germ cell mutations. There are numerous published studies
on the offspring of parents who have been exposed to high dose
radiation, chemotherapy and other toxicological agents that are
proven mutagens; if the exposure is high enough, infertility may
result. However, if fertility is intact, the offspring do notmanifest an
increase in cancer or hereditary diseases [31,34,56e77]. One addi-
tional consideration is that many deleterious mutations (sponta-
neousor as a result of preconception toxicityexposure)wouldnotbe
expressed as effects in the offspring because they are lethal to the
developing ova or sperm or to the very young developing embryo
because of defective ovaor sperm, a result that has beendescribed as
biological ﬁltration [9,42].
Down syndrome has been extensively studied as a possible
consequence of diagnostic X-ray procedures but an association has
not been established [83]. Somemedical studies have been plagued
by differential recall bias between mothers of affected and normalTable 5
Stochastic and threshold doseeresponse relationships of diseases produced by environm
Phenomenon Pathology Site D
Stochastic (LNTHa) Damage to a single cell
may result in disease
DNA
(genes and chromosomes)
C
Threshold
(deterministic effect)
(tissue reaction effect)
Multicellular injury Multiple, variable etiology,
affecting many cell and
organ processes
M
r
e
LNTH, linear no-threshold hypothesis.
a Modiﬁed from Brent [9].children, as well as publication bias in not reporting negative
ﬁndings [84].
Studies of cancer survivors are particularly important because
they are numerous and, most importantly, because the timing and
dose of their exposure to radiation (and potentially mutagenic
chemicals) is accurately documented. The rates of genetic defects in
offspring of survivors and of sibling controls were not statistically
signiﬁcant [34,56,59e69,72e82]. In a population of Danish children
born after their parent’s treatment with radiation, the risk of
congenital malformation was increased but was not statistically
signiﬁcant [risk ratio: 1.2 (95% conﬁdence interval: 0.9e1.8;
n ¼ 36)] [85] and there was no evidence of a correlation between
birth defects and gonadal dose, reconstructed on individual patient
treatment records (mean doses were 1.3 Gy to ovaries and 0.5 Gy to
testes) [34,79]. These data suggest that the agents and doses to
which these individuals have been exposed do not induce trans-
missible mutations in human spermatogonial stem cells and
resting oocytes at a frequency high enough to be detected over the
background of spontaneous mutations (Table 3).
(2) The spouse is pregnant or considering pregnancy and is
concerned about medications that she has been prescribed or is
taking, chemicals in the workplace, whether she should have an X-
ray suggested by her physician, concern about the power lines near
her home, the microwave oven in her kitchen, or numerous
frightening messages on the Internet. The most common concern is
whether their childmay be bornwith birth defects. Miscarriage and
mental retardation are next on their list, or whether their future
child is at increased risk for developing cancer.
If the family is concerned about medications prescribed for the
pregnant spouse or other environmental exposures that have been
extensively studied, the counselor may be able to determine
whether there extensive toxicological data have been published
and are available to the counselor. Table 1 lists about 60 environ-
mental toxicants that have been studied to determine their ability
to affect the developing embryo/fetus or that are alleged to have
affected the developing embryo/fetus. If the concern is about a
chemical exposure, the family may not know the name of the
chemical or the exposure, which makes it difﬁcult or impossible to
provide an adequate risk assessment. Several websites may be of
assistance (CDC, OMIM, TERIS; see Box 5).
After obtaining the toxicological information, the following
process should be initiated as suggested in Boxes 2 and 3.
(3) Since the risk of birth defects is 3% and miscarriage occurs in
15% of pregnancies in women after the ﬁrst missed menstrual
period, the familymay contact the counselor to explain the etiology
of the developmental or reproductive problem in their child (Box 3,
Table 2).
Determining the etiology of birth defects or miscarriage in an
individual infant or pregnancy can be a difﬁcult task, especially if
the description of the malformation is provided to the counselor by
the parent or the family physician. Second, this task could be veryental agents.
iseases Risk Deﬁnition
ancer, germ cell mutation Some risk exists at all
dosages; at low doses,
risk may be less
than spontaneous risk
The incidence of the
disease increases but
the severity and nature
of the disease remain
the same
alformation, growth
etardation, death, toxicity,
tc.
No increased risk below
the threshold dose
Both the severity and
incidence of the disease
increases with dose
Box 5
Websites.
CDC e Centers for Disease Control
www.cdc.gov/pregnancy.2009
OMIM e Online Mendelian Inheritance of Man
http://www3./ncbi.nlm.nih.gov/omim
Human Genome Project
www.geomics.energy.gov
TERIS e Teratogen Information System
http://apps.medical.washington.edu/teris/teris1a.aspx
(you need an ID and password, which can be obtained from
your university library or hospital if they have a subscrip-
tion). Shepard TH. Catalogue of teratogenic agents. 8th ed.
Baltimore: Johns Hopkins University Press; 1995 (now on
the TERIS website).
Health Physics Society
http://hps.org/documents/risk_ps010-2.pdf
OTIS e Organization of Teratology Information Specialists
www.mothertobaby.org
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appropriate to refer the family to a good genetic or dysmorphology
clinic.
(4) Determining whether to publish a case report of a patient or
a cluster of patients with a particular congenital malformation or a
constellation of congenital malformations that may be associated
with an exposure to an environmental agent [38].
Clinical evaluation of a child with congenital malformations by
an experienced and well-trained physicianwho is familiar with the
ﬁelds of developmental biology, teratology, epidemiology, and ge-
netics may be a simple or complex task. Too often, the entire
emphasis is placed on epidemiological data that may be meager or
insufﬁcient for a rational conclusion when clinical ﬁndings that are
readily available can provide deﬁnitive answers with regard to the
etiology of a child’s malformations or the merits of an environ-
mental etiology. Robert W. Miller [10] coined the term ‘the alert
physician’ because he observed that discoveries of toxic environ-
mental situations or agents were made by observant clinicians. A
review article by Brent [36] indicated that most new teratogens
were discovered by alert counselors, physicians or scientists, not by
epidemiological investigations. Epidemiological investigations
could be initiated in order to conﬁrm the alert scientist’s pre-
sumptive ﬁndings. Shepard emphasized that, if the teratogenic
syndrome observed in a group of toxicant-exposed patients was
rare and unique, the ﬁnding was worth pursuing because the
toxicant may be a new teratogen [28].
The editor of the American Journal of Medical Genetics requested
a teratologist to determine whether a submitted article should be
published since several pregnant women had been exposed to
misoprostol and the offspring had malformations that could be
produced by a vascular disruptive agent. The reviewer recom-
mended that the article should be published in order to stimulate
further research concerning this drug’s potential teratogenicity and
to alert health care workers about the fact that misoprostol might
be a new teratogen [38]. A clinician trained and experienced in
these ﬁelds can have a decisive role in utilizing the principles of
teratology (Box 4) and biological plausibility in evaluating the
allegation that a particular environmental agent was responsible
for a child’s congenital malformations [9,28,38e40,42,44,45]. Twoexcellent publications that discuss the utilization of teratology
principles and biologic plausibility have been published by Graham
et al. [45] and Carey et al. [44].
8. Conclusion
During the past century and especially since the end of World
War II, there have been many advances and discoveries in the ﬁelds
of teratology, developmental biology, genetics, radiology, obstet-
rics, reproductive toxicology and many other ﬁelds, improving the
care and diagnosis of children with birth defects. In the early years
of the twentieth century, medical education improved in the USA
through the efforts of the Carnegie Foundation and Abraham
Flexner. However, there were no educational programs for training
professionals on how to deal with environmental toxicants and
their risks or on dealing with patients or families who were con-
cerned about these risks. It was George Engle who introduced the
biopsychosocial model of health care, which taught that one should
not ignore the patient’s environmental and social defenses because
these determine how the patient will respond to the care program.
If the patient or contact does not sense that the counselor is
compassionate or empathetic, the care program will falter. Engle
and Rogers legitimized counseling. Rogers put the ﬁnal stamp on
this philosophy by indicating that the counselor’s task was to
convince the contact that the contact’s best interests were the
counselor’s highest priority (unconditional positive regard) [4].
The Teratology Society was chartered in 1961 and was the ﬁrst
group of clinicians and scientists who were interested in birth de-
fects. An offspring of the Teratology Society, OTIS, was more inter-
ested in counseling but never developed a program that certiﬁed
counselors. Genetics became a board-certiﬁed specialty that did
certify counselors. Similar birth defect organizations were formed
in Europe, Japan and Australia.
The review includes a summary of the drugs, chemicals and
physical agents that have been documented to result in congenital
malformations and reproductive effects when pregnant women are
exposed during pregnancy. The principles of teratology were also
summarized and emphasize that: (i) no teratogenic agent can be
described qualitatively as a teratogen, since a teratogenic exposure
must include not only the agent, but also the dose and the time in
pregnancy when the exposure occurs; (ii) even agents that have
been demonstrated to result in malformations cannot produce
every type of malformation; (iii) known teratogens can be pre-
sumptively identiﬁed by the spectrum of malformations they pro-
duce; (iv) it is easier to exclude an agent as a cause of birth defects
than to deﬁnitively conclude that it was responsible for birth de-
fects; (v) when evaluating the risk of exposures, the dose is a crucial
component in determining the risk; (vi) teratogenic agents follow a
toxicological doseeresponse curve e this means that each
teratogen has a threshold dose, below which there is no risk of
teratogenesis, no matter when in pregnancy the exposure
occurred; (vii) the evaluation of a child with congenital malfor-
mations cannot be adequately performed unless it is approached
with the same scholarship and detail as is any other complicated
medical problem; (viii) each physician must recognize the conse-
quences of providing erroneous reproductive risks to pregnant
women exposed to drugs and chemicals during pregnancy or
alleging that a child’s malformations are due to an environmental
agent without performing a complete and scholarly evaluation.
When a counselor responds to a parent’s inquiry (‘What caused
my child’s birth defect?’), the physician should respond in the same
scholarlymanner that would be utilized in performing a differential
diagnosis for any clinical problem. Physicians have a protocol for
evaluating complex clinical problems. If a mother of a malformed
infant had some type of exposure during pregnancy, such as a
R.L. Brent / Seminars in Fetal & Neonatal Medicine 19 (2014) 139e152 151diagnostic radiological examination or medication during preg-
nancy, the consulting physician should not support or suggest the
possibility of a causal relationship before performing a complete
evaluation. Likewise, if a pregnant woman who had not yet deliv-
ered had some type of exposure during pregnancy, the consulting
physician should not support or suggest the possibility that the
fetus is at increased risk before performing a complete evaluation.
Only a small percentage of birth defects are due to prescribed drugs,
chemicals and physical agents.
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